| scholarly article | Q13442814 |
| P2093 | author name string | Bing Wu | |
| Le-Ning Zhang | |||
| Hong-Bin Sun | |||
| Zhong-Feng Wang | |||
| Fu-Qiang Li | |||
| Li-Zhe Wang | |||
| Jun-Duo Wu | |||
| He-Yuan Wang | |||
| P2860 | cites work | Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 |
| Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response | Q28140763 | ||
| Cellular processing of platinum anticancer drugs | Q29617899 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study | Q33342456 | ||
| Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program | Q33406382 | ||
| The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population | Q33991747 | ||
| Osteosarcoma treatment - where do we stand? A state of the art review. | Q34392457 | ||
| Current strategies of chemotherapy in osteosarcoma | Q34569791 | ||
| Radiotherapy and cellular signalling | Q34571988 | ||
| International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons | Q34605959 | ||
| Adjuvant and neoadjuvant chemotherapy in osteosarcoma. | Q34677373 | ||
| Bystander effects and radiotherapy | Q34719561 | ||
| Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer--a review of their cooperation | Q35192078 | ||
| The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines | Q36218369 | ||
| The role of the BRCA1 tumor suppressor in DNA double-strand break repair | Q36299256 | ||
| A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer | Q36432567 | ||
| Chemotherapy resistance in osteosarcoma: current challenges and future directions. | Q36532115 | ||
| Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer | Q37314520 | ||
| The contribution of BRCA1 and BRCA2 to ovarian cancer | Q37453854 | ||
| The role of radiotherapy in oseosarcoma | Q37705045 | ||
| Heterogeneity in Cancer Metabolism: New Concepts in an Old Field | Q37713095 | ||
| Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? | Q37894250 | ||
| The role of BRCA1 in DNA double-strand repair: past and present | Q38064172 | ||
| Epigenetic alterations in osteosarcoma: promising targets | Q38185555 | ||
| Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis | Q38209068 | ||
| Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal | Q38349935 | ||
| Screening of diagnostic markers for osteosarcoma | Q38472812 | ||
| BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review | Q38538274 | ||
| An update on chemotherapy for osteosarcoma | Q38619114 | ||
| Osteosarcoma: A Meta-Analysis and Review of the Literature | Q38668801 | ||
| BRCAness revisited | Q38699280 | ||
| Re-calculating! Navigating through the osteosarcoma treatment roadblock | Q38784517 | ||
| Genetic and epigenetic heterogeneity and the impact on cancer relapse | Q39433546 | ||
| Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines | Q40126696 | ||
| Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma | Q40191105 | ||
| Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment | Q40652172 | ||
| Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics | Q41472115 | ||
| Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. | Q44197617 | ||
| Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. | Q45949539 | ||
| The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery | Q46528568 | ||
| Advances in limb salvage treatment of osteosarcoma | Q47117024 | ||
| CD155 knockdown promotes apoptosis via AKT/Bcl-2/Bax in colon cancer cells. | Q47154471 | ||
| The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis | Q47754317 | ||
| A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy | Q48345502 | ||
| Tumour heterogeneity and resistance to cancer therapies | Q50112440 | ||
| Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response. | Q53797260 | ||
| Carbon ion radiotherapy for inoperable pediatric osteosarcoma. | Q55017855 | ||
| Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities | Q72990248 | ||
| Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group | Q77838943 | ||
| Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group | Q78785367 | ||
| The sensitivity of BRCA1 mutation carriers to ionising radiation: questions of methodology | Q81340126 | ||
| A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma | Q83239231 | ||
| Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk | Q83498129 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 6385-6396 | |
| P577 | publication date | 2019-10-29 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments | |
| P478 | volume | 18 |
Search more.